Literature DB >> 2169995

Human papillomavirus type 16 associated with oral squamous carcinoma in a cardiac transplant recipient.

D J Demetrick1, M Inoue, W M Lester, I Kingma, M A Duggan, L C Paul.   

Abstract

Human papillomavirus type 16 (HPV 16) has been associated with a variety of squamous carcinomas, particularly those involving the anogenital tract. The authors report the development of an oropharyngeal carcinoma in a 43-year-old man approximately 20 months after cardiac transplantation while he was on a maintenance regimen of cyclosporine A and prednisone. The carcinoma was resistant to treatment, and he died of complications related to metastatic disease 3 years posttransplantation. Molecular biologic studies using nonisotopic-labeled viral DNA probes were done. In situ hybridization demonstrated the presence of HPV 16 DNA in the tumor cells. DNA dot blot analysis confirmed the presence of multiple copies of HPV 16 DNA within the tumor cells and their absence from adjacent normal-appearing tissue. Southern blot analysis suggested that the HPV 16 DNA was integrated into the tumor cell genome. With increasing recognition of the carcinogenicity of HPV type 16 infection, a role for this virus in the development of squamous cell malignancies in immunosuppressed organ transplant recipients is likely to be noted with increasing frequency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169995     DOI: 10.1002/1097-0142(19901015)66:8<1726::aid-cncr2820660814>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Human papillomavirus 16/18 and nasopharyngeal carcinoma.

Authors:  P Dickens; G Srivastava; Y T Liu
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

Review 2.  HPV infections and tonsillar carcinoma.

Authors:  S Syrjänen
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 3.  Human papillomavirus infections and oral tumors.

Authors:  Stina Syrjänen
Journal:  Med Microbiol Immunol       Date:  2003-01-18       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.